Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Prevention of AMR in ABOi-LDKTx
NCT06453135Phase 2Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in antibody mediated rejection (AMR). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
eculizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT06453135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453135.